Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,554
Total Claims
$1.3M
Drug Cost
943
Beneficiaries
$1,379
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+28%
Opioid rate vs peers
2.9% vs 2.2% avg
-2%
Cost per patient vs peers
$1,379 vs $1,411 avg
+23%
Brand preference vs peers
13.1% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
2.9%
Opioid Rate
332
Opioid Claims
$13K
Opioid Cost
3.3%
Long-Acting Rate
Brand vs Generic
Brand: 1,483 claims · $1.1M
Generic: 9,837 claims · $185K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 188 | $174K |
| Sitagliptin Phosphate | 117 | $117K |
| Empagliflozin | 78 | $105K |
| Semaglutide | 81 | $81K |
| Bictegrav/Emtricit/Tenofov Ala | 11 | $45K |
| Dulaglutide | 24 | $42K |
| Fluticasone/Umeclidin/Vilanter | 44 | $41K |
| Tirzepatide | 32 | $40K |
| Insulin Glargine,hum.Rec.Anlog | 48 | $33K |
| Denosumab | 19 | $32K |
| Rivaroxaban | 22 | $29K |
| Evolocumab | 33 | $25K |
| Insulin Detemir | 33 | $25K |
| Dapagliflozin Propanediol | 16 | $24K |
| Linagliptin | 18 | $22K |
Prescribing Profile
Patient Profile
75
Avg Age
53%
Female
0.97
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About